Clarity Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Clarity Pharmaceuticals has a total shareholder equity of A$146.3M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$154.6M and A$8.3M respectively.
Key information
0%
Debt to equity ratio
AU$0
Debt
| Interest coverage ratio | n/a |
| Cash | AU$136.51m |
| Equity | AU$146.30m |
| Total liabilities | AU$8.33m |
| Total assets | AU$154.63m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: CU6's short term assets (A$154.1M) exceed its short term liabilities (A$8.1M).
Long Term Liabilities: CU6's short term assets (A$154.1M) exceed its long term liabilities (A$242.9K).
Debt to Equity History and Analysis
Debt Level: CU6 is debt free.
Reducing Debt: CU6 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CU6 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CU6 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.